{"product_id":"resmed-five-forces-analysis","title":"ResMed Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eResMed faces intense rivalry in sleep and respiratory care, moderate supplier power due to specialized components, rising buyer sophistication, and growing substitute threats from digital therapeutics and homecare innovations; regulatory barriers limit new entrants but reimbursement shifts add pressure. This brief snapshot only scratches the surface — unlock the full Porter's Five Forces Analysis to explore force-by-force ratings, visuals, and actionable strategy for ResMed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized components concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed depends on niche suppliers for blowers, sensors, semiconductors and medical‑grade polymers, concentrating bargaining power among few qualified vendors; this raises switching costs and extends lead times. Supply disruptions can constrain production runs and limit pricing flexibility. Dual‑sourcing and design‑for‑manufacture reduce exposure but do not eliminate supplier concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and regulatory requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed relies on medical-grade QA and ISO 13485:2016 plus FDA 21 CFR Part 820 compliance, which narrows the supplier pool to those meeting device-quality systems and validated materials.\u003c\/p\u003e\n\u003cp\u003eHigh compliance costs and limited FDA-compliant material sources increase supplier leverage, while mandatory audits and multi-stage validation cycles lengthen supplier changeovers.\u003c\/p\u003e\n\u003cp\u003eSupplier failures can prompt device recalls and immediate regulatory scrutiny, exposing ResMed to corrective actions and market disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud and software dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCloud infrastructure and analytics partners create platform lock-in for ResMed, with AWS (≈33%), Azure (≈22%) and GCP (≈11%) dominating IaaS in 2024, raising supplier leverage. Uptime SLAs of 99.95–99.99%, data residency rules and cybersecurity needs heighten vendor importance and patient-data continuity risk. Switching providers is costly and operationally risky; negotiated volume discounts (often 5–15%) partially offset supplier power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing flexibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContract manufacturing adds surge capacity for ResMed but EMS\/ODM partners can gain leverage during tight global supply; ResMed reported approximately US$4.7 billion revenue in fiscal 2024, underscoring heavy manufacturing scale reliance. Tooling, custom firmware, and partner know-how create supplier stickiness, while geographic diversification and long-term volume agreements reduce single-point exposure and price pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply leverage: EMS\/ODM can tighten terms during shortages\u003c\/li\u003e\n\u003cli\u003eStickiness: tooling + firmware embed partner dependence\u003c\/li\u003e\n\u003cli\u003eMitigants: geographic diversification, volume visibility, long-term contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput cost volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInput cost volatility: in 2024 resin, electronics and logistics remained cyclical with suppliers able to pass through price spikes during shortages; hedging and larger inventories have cushioned ResMed margins but increased working capital, and design substitutions trigger device revalidation that slows response times.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResins, electronics, logistics cyclical in 2024\u003c\/li\u003e\n\u003cli\u003eSuppliers can pass through costs during shortages\u003c\/li\u003e\n\u003cli\u003eHedging\/inventory protect margins but tie up working capital\u003c\/li\u003e\n\u003cli\u003eDesign substitutions require revalidation, slowing response\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration, cloud reliance and regulatory QA raise switching costs for CPAP makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed faces concentrated supplier power for blowers, sensors, semiconductors and medical polymers, raising switching costs and lead times; FY2024 revenue ≈ US$4.7B heightens scale dependence. Regulatory QA (ISO 13485, FDA) and cloud\/IaaS reliance (AWS 33%, Azure 22%, GCP 11% in 2024) increase vendor leverage; mitigants include dual‑sourcing, long‑term contracts and geographic diversification.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eUS$4.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAWS\/Azure\/GCP\u003c\/td\u003e\n\u003ctd\u003e33%\/22%\/11%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime SLA\u003c\/td\u003e\n\u003ctd\u003e99.95–99.99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for ResMed uncovering competitive intensity, buyer and supplier power, threat of substitutes and new entrants, plus disruptive trends in digital health and home sleep apnea therapy; strategic commentary and industry data highlight pricing pressure, margins, and barriers protecting incumbency for use in investor reports and strategy decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise ResMed Porter's Five Forces one-sheet highlighting supplier, buyer, substitute, entrant, and competitive rivalry pressures—easy to adjust for evolving healthcare regulations, device innovation, and reimbursement shifts to guide fast strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated institutional buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConcentrated buyers—DMEs, hospital systems and sleep-lab networks—negotiate bulk contracts, with GPOs representing the majority of hospital procurement and driving discounts of roughly 5–20%. Large accounts extract rebates and tight service SLAs; ResMed reported FY2024 revenue of about $4.7 billion, so losing a few key contracts can cut double-digit regional share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and reimbursement influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers shape ResMed demand through coverage rules and rental versus purchase policies, with Medicare CPAP adherence defined as ≥4 hours\/night on ≥70% of nights during a consecutive 30‑day period within the first 90 days. Competitive bidding has compressed margins—CMS reported average bid price reductions up to ~40% in some rounds—so maintaining evidence-based outcomes is critical to preserve codes and pricing; tightened adherence rules lower device utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct differentiation and switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's mask-fit ecosystems, connected compliance and clinician portals create strong stickiness, reinforced by over 7 million cloud-connected devices reported by 2024. Data continuity and patient familiarity materially reduce switching, as clinicians cite 1–2 hours average setup\/training per patient. Standardized interfaces mean competitors can win share if price gaps exceed roughly 15%. Training and ongoing support remain key buyer considerations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician prescribing power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinicians largely determine device choice through experience and outcomes, with strong KOL advocacy shown to lift adoption rates materially; recalls (eg, the 2021 Philips CPAP recall) caused \u0026gt;30% rapid shifts in prescription patterns in some centers. Education, telemonitoring and support programs have been associated with ~10–15% higher CPAP adherence, strengthening brand loyalty and countering pure price competition.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician-driven choice: primary demand driver\u003c\/li\u003e\n\u003cli\u003eKOL advocacy: increases adoption materially\u003c\/li\u003e\n\u003cli\u003eRecalls: can shift \u0026gt;30% prescriptions quickly\u003c\/li\u003e\n\u003cli\u003eEducation\/support: ~10–15% adherence lift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnd-user sensitivity and outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients prioritize comfort, noise and aesthetics, driving churn; CPAP adherence averages around 50%, while Medicare requires ≥4 hours\/night on 70% of nights for coverage, heightening price sensitivity. Remote monitoring and coaching demonstrably lift adherence and enable value-based pricing; co-pays (Medicare Part B 20% coinsurance) increase price sensitivity. Consumer reviews and telehealth pathways heavily shape brand choice.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003etags: adherence ~50%\u003c\/li\u003e\n\u003cli\u003etags: Medicare rule 70% ≥4 hrs\u003c\/li\u003e\n\u003cli\u003etags: Medicare coinsurance 20%\u003c\/li\u003e\n\u003cli\u003etags: remote monitoring → higher adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated buyers push \u003cstrong\u003e5–20%\u003c\/strong\u003e cuts; lost contracts threaten \u003cstrong\u003e$4.7B\u003c\/strong\u003e revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated buyers (DMEs, GPOs, hospitals) extract 5–20% discounts; ResMed FY2024 revenue ≈ $4.7B so lost contracts can cut double-digit regional share. Payers (Medicare: ≥4 hrs\/night on ≥70% nights; 20% coinsurance) and CMS bidding (up to ~40% price cuts) compress pricing. Product stickiness (7M+ cloud devices in 2024) and clinician\/KOL influence raise switching costs; price gaps \u0026gt;15% invite churn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003cth\u003eBuyer Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$4.7B\u003c\/td\u003e\n\u003ctd\u003eHigh contract risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected devices\u003c\/td\u003e\n\u003ctd\u003e7M+\u003c\/td\u003e\n\u003ctd\u003eHigh retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO discounts\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS bid cuts\u003c\/td\u003e\n\u003ctd\u003eUp to ~40%\u003c\/td\u003e\n\u003ctd\u003ePrice compression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eResMed Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ResMed Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups. The document is the full, professionally formatted analysis covering competitive rivalry, supplier and buyer power, threat of substitutes, and barriers to entry. Once you buy, you’ll get instant access to this identical, ready-to-use file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163034726777,"sku":"resmed-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/resmed-five-forces-analysis.png?v=1762713320","url":"https:\/\/portersfiveforce.com\/products\/resmed-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}